Plasma Fractionation Market: United States Dominates as the Hub of Plasma Collection Centers, Asia-Pacific Shows Promising Growth

DUBLIN, Oct. 2, 2023 /PRNewswire/ -- The "Plasma Fractionation Market by Type of Company, Scale of Operation, Type of Plasma-derived Therapeutic Products Manufactured, Therapeutic Areas of Plasma-derived Products and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035" report has been added to  ResearchAndMarkets.com's offering.

The global plasma fractionation market is currently estimated to be worth $5 billion in 2023 and is poised to exhibit a compounded annual growth rate (CAGR) of approximately 10% during the forecast period from 2023 to 2035. The increasing prevalence of rare diseases and the rising demand for plasma-derived therapies are driving the growth of this market.

Key Market Dynamics

• Rise in Rare Diseases: Over the past two decades, the number of patients affected by rare diseases has significantly increased, with over 410 million people currently suffering from rare and chronic disorders. This has led to a growing demand for plasma-derived therapies, which have proven to be effective treatment options for these conditions.
• Plasma Collection Centers in the US: Currently, the United States is home to approximately 80% of the world's plasma donation centers. The country supplies over 70% of the plasma used in the manufacturing of plasma-derived therapies through the process of plasma fractionation.
• Importance of Plasma Fractionation: Plasma fractionation is a critical process for separating and purifying key blood plasma components, including immunoglobulins, albumins, anticoagulant factors, and protease inhibitors. These refined components are used to formulate lifesaving therapeutics.
• Recent Approvals: In April 2023, HYQVIA, a recombinant immunoglobulin, received approval for its expanded usage in the treatment of primary immunodeficiency in children aged 2-16 years. Such approvals underscore the significance of plasma-derived therapies in treating rare and complex diseases.

Challenges and Solutions

• Shortage in Plasma Donations: The COVID-19 pandemic led to a 20% reduction in plasma donations, resulting in a shortage of raw materials for plasma-derived therapies. To address this, various stakeholders, including government agencies and plasma fractionation companies, launched awareness campaigns to encourage plasma donation.
• Market Consolidation: The market is consolidated, with large commercial plasma fractionators acquiring smaller regional players. Companies like Takeda and Grifols have acquired plasma collection centers to ensure a stable supply of plasma.
• Advancements in Plasma Collection: Efforts are underway to enhance the efficiency and reduce the cost of plasma-derived therapies. Technological advancements in plasma collection, such as the Rika Plasma Donation System, aim to improve the donor experience and reduce procedure times.

Market Analysis

• Distribution of Companies: The plasma fractionation market includes a mix of large, mid-sized, and small companies involved in the manufacturing of various plasma-derived products. More than 35 companies perform plasma fractionation in-house to manufacture these therapies.
• Geographical Presence: Over 85 plasma facilities have been identified worldwide, with the majority located in the Asia-Pacific region. Nearly 20% of plasma fractionation companies can operate at all scales, from preclinical to commercial.
• Product Segmentation: Immunoglobulins represent the largest segment in the plasma fractionation market, capturing over 45% of market share and expected to grow at a CAGR of 12% during the forecast period.
• Demand and Supply: Currently, approximately 45% of demand for plasma-derived therapies is generated from North America. However, the Asia-Pacific region is expected to witness significant growth in demand, driven by increased awareness and the potency of plasma-derived products.

Leading Companies

Key players in the plasma fractionation market include Baxter, Grifols, Kedrion, Octapharma, CSL, and Takeda Pharmaceutical, among others.

Recent Developments

• In June 2023, GC Biopharma received approval to build a plasma fractionation plant in Indonesia.
• In March 2023, Bio Products Laboratory (BPL) established a strategic partnership with CSI Pharmacy to provide limited distribution rights to BPL's immune globulin product Gammaplex.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. PLASMA FRACTIONATION: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Plasma Fractionation: Overall Market Landscape

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: In-house Manufacturers
5.5. Company Competitiveness Analysis: In-house Manufacturers and Contract Service Providers

6. COMPANY PROFILES

7. PARTNERSHIPS AND COLLABORATIONS

8. RECENT EXPANSIONS

9. CAPACITY ANALYSIS

10. MARKET SIZING AND OPPURTUNITY ANALYSIS

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS

13. APPENDIX I: TABULATED DATA

14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

• Accenture
• ADMA Biologics
• Aegros
• Akron Biotech
• AlfaBioVIZ
• Alkahest
• Alpha Therapeutics (acquired by Grifols)
• Amazon Web Services (AWS)
• Ampersand
• Armour Pharmaceutical
• Atlantic Research
• Aventis Behring (acquired by CSL)
• Baxalta (acquired by Shire)
• Baxter
• Behringwerke
• Benesis (merged with Mitsubishi Tanabe Pharma)
• Bio Nordix
• Bio Products Laboratory (BPL)
• Biomedical Advanced Research Development Authority (BARDA)
• Biopharma
• Biotest
• Biovitrum (acquired by Octapharma)
• Blood and Plasma Research
• Bloodbuy
• Boccard
• BPL Plasma (subsidiary of Bio Products Laboratory)
• CAF-DCF
• Canadian Blood Services
• Catalyst Biosciences
• Celestial Biologicals (subsidiary of Intas Pharmaceuticals)
• Centeon (subsidiary of CSL)
• Centurion Pharma
• Chemgineering
• China Biologic Products Holdings
• China National Biotec Group (CNBG) (subsidiary of Sinopharm)
• China Resources Boya Bio-Pharmaceutical
• Columbia University Irving Medical Center (CUIMC)
• Cryoport Systems
• CSI Pharmacy
• CSL
• Cutter Laboratories (acquired by Bayer)
• Deutsches Rotes Kreuz (Springe facility is acquired by Octapharma)
• Edgewater Capital Partners
• Elektrofi
• Elomatic
• Endpoint Health
• Essentia Protein Solutions
• Evolve Biologics
• GC Biopharma (formerly known as GC Pharma)
• Grifols
• Haema
• Hayat Biotech
• Hemarus Therapeutics
• Hemogam
• HLL Lifecare
• Hualan Biological Engineering
• Hyland Therapeutics (acquired by Baxter)
• Immuno (merged with Baxter)
• ImmunoTek
• Intas Pharmaceuticals
• ISI (subsidiary of Kedrion)
• Kaketsuken (acquired by Meiji Holdings)
• Kamada Pharmaceuticals
• Kedrion
• LEBAS INDUSTRIES
• Lee's Pharmaceutical
• Leinco Technologies
• LFB
• Liminal BioSciences
• Maxicells
• Melville Biologics (spin-off from New York Blood Center)
• Merck KGaA
• Ministry of Health (Israel)
• Mitsubishi Tanabe Pharma
• National Resilience
• National Service Projects Organization (NSPO)
• NE Engineering (Shanghai)
• Neste Jacobs
• Octapharma
• Olsa
• Oryx Bio-Tech
• Pall Corporation
• Permira
• Pharma Pharmaceutical Industries (PPI)
• Plasma Technologies
• PlasmaGen BioSciences
• Precision Pharma (acquired by Talecris Biotherapeutics)
• PrIME Biologics (spin-off from NuSep)
• Probifasa (acquired by Octapharma)
• Prolytix (formerly known as Haematologic Technologies)
• Promea Therapeutics
• ProMetic BioTherapeutics (acquired by Kedrion)
• ProThera Biologics
• Prothya Biosolutions
• Purissmus
• Reliance Life Sciences
• Samarth Life Sciences
• Sanaplasma
• Sanquin
• Selagine
• Shanghai Canbi Pharma
• Shanghai RAAS Blood Products
• Shire (acquired by Takeda)
• Sichuan Yuanda Shuyang Pharmaceutical
• SK Chemicals
• Taibang Biological Products
• Taj Pharmaceuticals
• Takeda Pharmaceutical
• Talecris Biotherapeutics (acquired by Grifols)
• TECNinox
• Tiancheng Pharmaceutical
• V.I. Technologies (Vitex) (formerly known as Melville Biologics)
• Virchow Biotech
• ZETA
• ZLB

For more information about this report visit https://www.researchandmarkets.com/r/ipunjb

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets